Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity pill shows promise in early trial

NCT ID NCT06717425

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new daily pill called PF-07976016 in 263 adults with obesity. Participants received either the active drug or a placebo for several weeks. Researchers measured weight changes and tracked any side effects to see if the drug is safe and helps with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07976016 (a daily pill for weight loss)
What this could lead to
If successful, this could lead to a new daily medication to help people with obesity lose weight safely.
What could go wrong
This is an early Phase 2a trial, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

263 people

The number who actually took part.

Started

Dec 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1 * Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1 * Eligible and willing to receive required background medicine * Willing and able to comply with all study procedures Key Exclusion Criteria: * Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes. * Use of any prohibited prior or concomitant medication(s) * Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • AMR Clinical

    Norman, Oklahoma, 73069, United States

  • Accellacare - Wilmington

    Wilmington, North Carolina, 28401, United States

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States

  • Artemis Institute for Clinical Research

    San Diego, California, 92103, United States

  • Canadian Phase Onward

    Toronto, Ontario, M3J 0K2, Canada

  • Capital Area Research, LLC

    Camp Hill, Pennsylvania, 17011, United States

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Pomeranian Voivodeship, 81-338, Poland

  • Centrum Zdrowia Metabolicznego Pawel Bogdanski

    Poznan, Greater Poland Voivodeship, 60-589, Poland

  • Chrysalis Clinical Research

    St. George, Utah, 84790, United States

  • Clinical & Translational Research Center

    Aurora, Colorado, 80045, United States

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Cornerstone Nutrition and Diabetes

    Norman, Oklahoma, 73069, United States

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606, United States

  • Dawson Clinical Research Inc.

    Guelph, Ontario, N1H 1B1, Canada

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • Ekamed

    Lublin, Lublin Voivodeship, 20-718, Poland

  • Elligo Clinical Research Center

    Austin, Texas, 78704, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Medicome Sp. z o. o.

    Oświęcim, Lesser Poland Voivodeship, 32-600, Poland

  • Milestone Research Inc.

    London, Ontario, N5W 6A2, Canada

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808, United States

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • Renstar Medical Research

    Ocala, Florida, 34471, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia, 30291, United States

  • Selma Medical Associates

    Winchester, Virginia, 22601, United States

  • Southwest Internal Medicine, PC

    St. George, Utah, 84790, United States

  • St Johns Center for Clinical Research

    Saint Augustine, Florida, 32086, United States

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303, United States

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas, 78749, United States

  • The Wharton Medical Clinic Clinical Trials Inc.

    Hamilton, Ontario, L8L 5G8, Canada

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Westside Center for Clinical Research

    Jacksonville, Florida, 32205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.